ATE530198T1 - Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist - Google Patents

Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist

Info

Publication number
ATE530198T1
ATE530198T1 AT06723047T AT06723047T ATE530198T1 AT E530198 T1 ATE530198 T1 AT E530198T1 AT 06723047 T AT06723047 T AT 06723047T AT 06723047 T AT06723047 T AT 06723047T AT E530198 T1 ATE530198 T1 AT E530198T1
Authority
AT
Austria
Prior art keywords
cancer
mmp
replaced
furine
immunotoxin
Prior art date
Application number
AT06723047T
Other languages
English (en)
Inventor
Uwe Zangemeister-Wittke
Paolo Claudio Di
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE530198T1 publication Critical patent/ATE530198T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06723047T 2005-02-16 2006-02-16 Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist ATE530198T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65311205P 2005-02-16 2005-02-16
PCT/EP2006/001421 WO2006087196A2 (en) 2005-02-16 2006-02-16 Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9

Publications (1)

Publication Number Publication Date
ATE530198T1 true ATE530198T1 (de) 2011-11-15

Family

ID=36916817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06723047T ATE530198T1 (de) 2005-02-16 2006-02-16 Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist

Country Status (6)

Country Link
US (1) US20090214543A1 (de)
EP (1) EP1848462B1 (de)
JP (1) JP5014157B2 (de)
AT (1) ATE530198T1 (de)
CA (1) CA2597638A1 (de)
WO (1) WO2006087196A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052322A1 (en) * 2006-10-30 2008-05-08 Viventia Biotech Inc. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
DK2197903T3 (en) * 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
WO2012123755A1 (en) * 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
PT2829283T (pt) * 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina

Also Published As

Publication number Publication date
US20090214543A1 (en) 2009-08-27
CA2597638A1 (en) 2006-08-24
WO2006087196A3 (en) 2007-04-19
JP2008530164A (ja) 2008-08-07
EP1848462A2 (de) 2007-10-31
EP1848462B1 (de) 2011-10-26
WO2006087196A2 (en) 2006-08-24
JP5014157B2 (ja) 2012-08-29

Similar Documents

Publication Publication Date Title
UA90209C2 (ru) Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
ATE459653T1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
NO20084480L (no) Diaryltiohydantoin forbindelser
ATE257128T1 (de) Schwefelfreies lignin und dessen derivate zur herabsetzung der bildung von schleim und ablagerungen in industriellen anlagen
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
EP1622608A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009001440A (es) Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple.
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
ATE407698T1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE527350T1 (de) Verfahren und zusammensetzungen zur behandlung, hemmung und reversierung von bandscheibenerkrankungen
DE60334820D1 (de) Verfahren zur kontrolle von krebs
NZ741573A (en) Anti-cd43 antibody and use thereof for cancer treatment
ATE413441T1 (de) Verfahren zur befestigung und sicherung von ufern,abhängen, böschungen und zumindest teilweise in bewegten gewässern befindlichen bauwerken durch verbundstoffe aus mineralischen partikeln und einem epoxydharz
Kwaning et al. Review on Effects of Mining in Ghana: The Case of Obuasi Municipality
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
Andreen No virtue like necessity: dealing with nonpoint source pollution and environmental flows in the face of climate change
ATE480265T1 (de) Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen
WO2006087196A3 (en) Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
TR200707151T2 (tr) Mikrobesin gübreler için ayırıcı ajan.
DE602006012548D1 (de) Verfahren zur bekämpfung von algenverschmutztem wasser
ATE541584T1 (de) Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties